Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in BRAF V600E-Mutated Rare Cancers
NCT02034110Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in anaplastic thyroid cancer (ATC), biliary tract cancer (BTC), gastrointestinal stromal tumor (GIST), low-grade glioma (LGG), high-grade glioma (HGG), sponsored by Novartis. Started Mar 2014; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)biliary tract cancer (BTC)gastrointestinal stromal tumor (GIST)low-grade glioma (LGG)high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02034110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034110.